Interview: Dr. Amr Morsy – CEO, Rameda, Egypt
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
Rameda aims to become the most valuable emerging pharmaceutical company in Egypt. The company’s mission is to provide customers with quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements.
Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region.
Owners hired V-Konsult of Germany to create a state-of-the art design, and British Carter Construction company was contracted to build the Rameda’s facilities.
In 1999, Rameda entered into an agreement with Alcon to manufacture – under license – their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda.
In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry.
To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team.
Contact
Cairo Scientific Office
8 Geziret El Arab Street (23rd Floor), Mohandessin, Giza, Egypt
+(202) 376 130 46 / 58 / 74
+(202) 376 130 18
Factory
Second Industrial Zone, plot number 5
Sixth of October, Egypt
+( 202) 383 31887 – 383 31848
+(202) 383 31849
Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5…
The latest news from Egyptian healthcare and life sciences, including progress towards the launch of a massive new oncology hospital, why local manufacturer EIPICO is expanding into Kazakhstan, increased governmental…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
See our Cookie Privacy Policy Here
